Real-world efficacy and safety profile of low-dose cadonilimab in recurrent or metastatic cervical cancer as first-line therapy
BackgroundCadonilimab, a bispecific PD-1/CTLA-4 antibody, has activity in recurrent/metastatic cervical cancer (R/M CC), but high costs limit accessibility, especially in low- and middle-income countries. Hence, we aimed to assess whether lower dose of…